Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)broad
CURE-PDAC · Horizon Europe grant · 2022-10-01–2025-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patents with unmet medical needs. iOnctura’s unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I) interface, a multi cell-network that is responsible for driving tumour growth and survival as well as treatment resistance.Pancreatic cancer is one of the most lethal cancers associated with devastating impact on the quality of life of patients; current treatments are largely ineffective and there is a need for game-changing therapies. IOA-289, is a first in class autotaxin (ATX) inhibitor that tackles cancer growth and spread by affecting core mechanisms at the T-S-I interface.The EIC Accelerator funding for CURE-PDAC will allow iOnctura to accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials, reach a major value inflection point and attract further financial investment into the company.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| IONCTURA BV | NL | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.